KYMR (Kymera Therapeutics) Cash Flow for Dividends : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kymera Therapeutics Cash Flow for Dividends?

Kymera Therapeutics's cash flow for dividends for the three months ended in Dec. 2024 was $0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Kymera Therapeutics Cash Flow for Dividends Historical Data

The historical data trend for Kymera Therapeutics's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kymera Therapeutics Cash Flow for Dividends Chart

Kymera Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash Flow for Dividends

Get a 7-Day Free Trial

Kymera Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash Flow for Dividends	Get a 7-Day Free Trial															-	-	-	-	-

Kymera Therapeutics Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Kymera Therapeutics Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of Kymera Therapeutics's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.

Kymera Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kymera Therapeutics Inc (NAS:KYMR) » Definitions » Cash Flow for Dividends

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 North Beacon Street, 4th Floor, Watertown, MA, USA, 02472

Website

https://www.kymeratx.com

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

Executives

Ellen Chiniara	officer: Chief Legal Officer	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Jared Gollob	officer: Chief Medical Officer	C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Bruce N. Jacobs	officer: Chief Financial Officer	C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Jeremy G Chadwick	officer: Chief Operating Officer	C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472
Pamela Esposito	director	C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Jeffrey W. Albers	director	BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Bruce Booth	director	890 WINTER STREET, SUITE 320, WALTHAM MA 02451
Joanna Horobin	director	215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142
Atlas Venture Fund X, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Victor Sandor	director	C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Leigh Morgan	director	KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472
John Maraganore	director	75 SIDNEY ST, CAMBRIDGE MA 02139
Nello Mainolfi	director, officer: President and CEO	C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Richard Chesworth	officer: Chief Scientific Officer	C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472